Mivocabtagene Autoleucel CD19 Chimeric Antigen Receptor T-Cell Therapy in Stiff Person Syndrome

In this nonrandomized clinical trial, a single dose of mivocabtagene autoleucel resulted in immunotherapy-free remissions with a consistent, well-tolerated safety profile, demonstrating a highly effective therapy in antibody-positive SPS with the potential for durable remissions. Long-term follow-up is ongoing.

Corresponding Author: Marinos C. Dalakas, MD, PhD, Department of Neurology, Thomas Jefferson University, 901 Walnut St, Ste 400, Philadelphia, PA 19107 (marinos.dalakas@jefferson.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.